BTAIQ BioXcel Therapeutics, Inc.
Pharmaceutical Preparations · OTC · SEC CIK 1720893 · Fiscal year ends 12/31
Financial factors as of 2026-06-30 (2026Q2), TTM = sum of the last four quarters
Growth
TTM revenue YoY-14.5%
TTM net income YoY-39.1%
TTM EPS YoY78.3%
Revenue 3-yr CAGR-10.6%
Net income 3-yr CAGR—
Margins
Gross margin53.1%
Operating margin-6,054.7%
Net margin-9,549.9%
FCF margin-6,860.4%
EBITDA margin-6,024.4%
Returns
ROE—
ROA-259.6%
ROIC (approx.)—
Asset turnover0.03x
Leverage & solvency
Liabilities / assets500.9%
Debt / equity—
Current ratio0.21x
Interest coverage-2.61x
Cash quality & payout
Operating cash flow / net income0.72x
Accruals ratio-73.1%
Payout ratio—
Capex / revenue0.0%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $642,000 | $2.27M |
| Cost of revenue | $164,000 | $2.14M |
| Gross profit | $478,000 | $123,000 |
| R&D expense | $30.25M | $30.43M |
| SG&A expense | $20.49M | $34.49M |
| Operating income | -$50.46M | -$67.25M |
| Interest expense | $16.98M | $15.13M |
| Income tax | $0 | $0 |
| Net income | -$69.90M | -$59.60M |
| EBITDA | -$50.16M | -$66.94M |
| EPS (basic) | -5.73 | -23.51 |
| EPS (diluted) | -5.73 | -23.51 |
| Weighted avg. shares (diluted) | 12.21M | 2.54M |
| Balance sheet | ||
| Cash & equivalents | $28.41M | $29.85M |
| Receivables | $233,000 | $131,000 |
| Inventory | $722,000 | $679,000 |
| Current assets | $44.69M | $37.39M |
| PP&E, net | $175,000 | $475,000 |
| Total assets | $44.92M | $38.34M |
| Current liabilities | $53.93M | $22.23M |
| Short-term debt | $24.93M | $0 |
| Long-term debt | $84.66M | $102.51M |
| Total debt | $109.59M | $102.51M |
| Total liabilities | $140.38M | $131.44M |
| Shareholders' equity | -$95.46M | -$93.10M |
| Net debt | $81.18M | $72.65M |
| Shares outstanding | 22.33M | 3.10M |
| Cash flow statement | ||
| Operating cash flow | -$57.62M | -$72.03M |
| Capital expenditure | $0 | $0 |
| Free cash flow | -$57.62M | -$72.03M |
| Investing cash flow | $0 | $0 |
| Financing cash flow | $56.52M | $36.66M |
| Depreciation & amortization | $300,000 | $309,000 |
| Stock-based compensation | $2.77M | $6.16M |
Free plan shows the latest 2 periods; Pro shows all 9 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.